

## Newborn Screening, Inborn Errors of Metabolism

## AB049. Diagnosis and treatment of phenylketonuria in Taiwan- experience from a national newborn screening confirmatory center

Chih-Ya Cheng, Ting-Rong Hsu, Chia-Feng Yang, Tzu-Hung Chu, Yung-Hsiu Lu, Sheng-Kai Chang, Dau-Ming Niu

Department of Pediatrics, Taipei Veterans General Hospital, Taipei, Taiwan

**Background:** Newborn screening for phenylketonuria has been started in Taiwan since 1985. Until December 2016, a total of >3 million newborns had been screened by our team.

**Methods:** Data from newborn screening, follow up test, treatment and clinical outcome were reviewed. Mutation analysis was performed as indicated.

**Results:** The incidence of hyperphenylalaninemia patients who need treatment is around 1/58,000 in Taiwan. The most common mutations of *PAH* gene are R241C and R408Q which accounts for 23.2% and 12.0% of the mutant alleles, respectively. Both mutations have been suggested to be a mild and being BH4 responsive. Under the therapy of PKU special formula or BH4, most of our PAH PKU

patients reach a normal IQ. The average IQ score of them is 98. The incidence of 6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency is around 1/116,000. N52S (52%) and P87S (30%) were the two most common mutations in our population for this disease. All patients received tetrahydrobiopterin replacement in a daily dosage between approximately 2 and 4 mg/kg. The dosages of levodopa replacement were 10–15 mg/kg/d, which is considerably higher than the typically recommended dosages of less than 7 mg/kg/d for patients aged <2 years and 8–10 mg/kg/d for patients aged ≥2 years. Replacement with 5-hydroxytryptophan varied widely among patients. The mean (SD) IQ score of our PTPS-deficient patients was 96.7 (9.7; range 86–119), which was considerably higher than previous reports of other populations of PTPS-deficient patients.

**Conclusions:** Local data of each country is essential for designing treatment strategy best suit for specific population.

**Keywords:** Phenylketonuria; PAH; 6-pyruvoyl-tetrahydropterin synthase (PTPS); tetrahydrobiopterin; newborn screening

doi: 10.21037/atm.2017.s049

**Cite this abstract as:** Cheng CY, Hsu TR, Yang CF, Chu TH, Lu YH, Chang SK, Niu DM. Diagnosis and treatment of phenylketonuria in Taiwan- experience from a national newborn screening confirmatory center. *Ann Transl Med* 2017;5(Suppl 2):AB049. doi: 10.21037/atm.2017.s049